Pyxis Oncology (PYXS) EBT (2020 - 2026)

Pyxis Oncology (PYXS) has reported EBT for 7 consecutive years, with -$25.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT fell 40.26% year-over-year to -$25.3 million in Q2 2026; TTM through Jun 2026 was -$82.4 million, a 16.48% increase from a year earlier, with the FY2025 full-year figure at -$78.2 million, up 1.59% from the prior year.
• EBT was -$25.3 million for Q2 2026 at Pyxis Oncology, down from -$17.0 million in the prior quarter.
• Over five years, EBT peaked at -$4.0 million in Q1 2024 and troughed at -$37.7 million in Q4 2024.
• A 5-year average of -$22.4 million and a median of -$21.7 million in 2025 frame the typical range for EBT.
• Across the five-year window, EBT jumped 79.23% in 2024 and plunged 441.15% in 2025, its largest moves.
• Over 5 years, EBT stood at -$36.1 million in 2022, then jumped by 55.2% to -$16.2 million in 2023, then tumbled by 133.32% to -$37.7 million in 2024, then jumped by 54.94% to -$17.0 million in 2025, then slumped by 49.07% to -$25.3 million in 2026.
• The last three EBT figures came in at -$25.3 million (Q2 2026), -$17.0 million (Q4 2025), and -$22.0 million (Q3 2025), per Business Quant data.